|
Hyperpolarized 13C-Pyruvate Clinical Trials
10 actively recruiting trials across 3 locations
Also known as: (13C) pyruvate, HP 13C, HP [1-13C]pyruvate, HP-13C, Hyperpolarized (HP) carbon^13 (13C)-pyruvate +2 more
Pipeline
Early 1: 1Phase 1: 2Phase 2: 3Phase 1/2: 2
Top Sponsors
- University of Maryland, Baltimore3
- University of California, San Francisco2
- University of Texas Southwestern Medical Center1
- Sunnybrook Health Sciences Centre1
- Robert Bok, MD, PhD1
Indications
- Cancer10
- Prostate Cancer2
- Warburg Effect1
- Heart Disease1
- Cardiometabolic Syndrome1
San Francisco, California4 trials
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
University of California, San Francisco
Phase 1/2
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
University of California, San Francisco
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
University of California, San Francisco
Phase 2
Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
University of California, San Francisco
Early 1
Baltimore, Maryland3 trials
HP Pyruvate MRI in Cancers
University of Maryland Medical Center
Phase 1/2
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
Rosy Njonkou Tchoquessi
Phase 1
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
University of Maryland Medical Center
Phase 2
Other2 trials
Dallas, Texas1 trial
Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
UT Southwestern Medical Center
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.